Olatec is a privately-owned biotech company leading the clinical development of oral, first-in-class anti-inflammatory drugs for acute and chronic indications. The lead compound, dapansutrile, is a specific inhibitor of the NLRP3 inflammasome, and inhibits the production of IL-1β, a prototypical inflammatory mediator of innate immunity. Olatec’s dapansutrile is a leader in the clinical development of the NLRP3 class. Several precedent activities involving acquisitions of other selective NLRP3 inhibitor companies are leading the interest from partners in the NLRP3 space. Recent partnerships and acquisitions publicly announced in the space include: • Ventus Therapeutics & Novo Nordisk - licensing of preclinical compound for $70 million up front • Roche acquired Inflazome Ltd. for $450 million - • Novartis IFM Tre for $310 million upfront -